CoChat

Clinical Impact of Initiating Insulin Glargine Therapy with Disposable Pen Versus Vial in Patients with Type 2 Diabetes Mellitus in a Managed Care Setting

Davis, Stephen N., Wei, Wenhui, Garg, Satish · 2011 · Endocrine Practice
Cited by 31

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4158/ep10401.or

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 20

  1. Huang, 2009, Projecting the future diabetes population size and related costs for the U. S., Diabetes Care, 32, 2225, 10.2337/dc09-0459 · DOI · Paper page
  2. Hoerger, 2008, Is glycemic control improving in U. S. adults?, Diabetes Care, 31, 81, 10.2337/dc07-1572 · DOI · Paper page
  3. Dodd, 2009, Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004, Curr Med Res Opin, 25, 1605, 10.1185/03007990902973300 · DOI · Paper page
  4. Oliveria, 2007, Barriers to the initiation of, and persistence with, insulin therapy, Curr Med Res Opin, 23, 3105, 10.1185/030079907X242638 · DOI
  5. Karter, 2010, Barriers to insulin initiation: the Translating Research Into Action for Diabetes insulin starts project, Diabetes Care, 33, 733, 10.2337/dc09-1184 · DOI · Paper page
  6. Korytkowski, 2003, A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus, Clin Ther, 25, 2836, 10.1016/S0149-2918(03)80337-5 · DOI · Paper page
  7. Summers, 2004, Preference for insulin delivery systems among current insulin users and nonusers, Clin Ther, 26, 1498, 10.1016/j.clinthera.2004.09.009 · DOI
  8. Goldstein, 2008, Pen devices to improve patient adherence with insulin therapy in type 2 diabetes, Postgrad Med, 120, 172, 10.3810/pgm.2008.09.1917 · DOI
  9. Ignaut, 2009, Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen, Diabetes Educ, 35, 789, 10.1177/0145721709340056 · DOI · Paper page
  10. Haak, 2007, Comparison of usability and patient preference for the new disposable insulin device SoloStar versus Flexpen, Lilly disposable pen, and a prototype pen: an open-label study, Clin Ther, 29, 650, 10.1016/j.clinthera.2007.04.003 · DOI
  11. Schwartz, 2008, Validation of the SoloSTAR insulin pen, Diabetes Technol Ther, 10, 351, 10.1089/dia.2008.0079 · DOI
  12. Hermanns, 2008, Dosing accuracy with a novel pen device (SoloSTAR) as performed by patients with diabetes in a clinical setting, Diabetes Technol Ther, 10, 322, 10.1089/dia.2008.0035 · DOI
  13. Krzywon, 2010, Dosing accuracy of commonly used disposable insulin pens, Curr Med Res Opin, 26, 901, 10.1185/03007991003608878 · doi:10.1185/03007991003608878
  14. Rosenbaum, 1983, The central role of the propensity score in observational studies for causal effects, Biometrika, 70, 41, 10.1093/biomet/70.1.41 · DOI · Paper page
  15. Cooke, 2010, Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization, Curr Med Res Opin, 26, 231, 10.1185/03007990903421994 · DOI · Paper page
  16. Pawaskar, 2007, Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis, Clin Ther, 29, 1294, 10.1016/j.clinthera.2007.07.007 · DOI
  17. Hertz, 2005, Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance, Clin Ther, 27, 1064, 10.1016/j.clinthera.2005.07.009 · DOI · Paper page
  18. Rakel, 2009, Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy, Adv Ther, 26, 838, 10.1007/s12325-009-0061-2 · DOI
  19. Asakura, 2009, A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen), Diabetes Technol Ther, 11, 657, 10.1089/dia.2009.0006 · DOI · Paper page
  20. D'Agostino, 1998, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group, Stat Med, 17, 2265, 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b

Cited by

See all 31

Metadata

Authors
Davis, S. N., Wei, W., & Garg, S.
Venue
Endocrine Practice
Publisher
Elsevier BV
Published
2011-11
Volume
17
Issue
6
Pages
845-852
ISSN
1530-891X
Cited by
31
References
2
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Impact of Initiating Insulin Glargine Therapy with Disposable Pen Versus Vial in Patients with Type 2 Diabetes Mellitus in a Managed Care Setting. https://app.cochat.ai/papers/10.4158/ep10401.or
The paper
Davis, S. N., Wei, W., & Garg, S. (2011). Clinical Impact of Initiating Insulin Glargine Therapy with Disposable Pen Versus Vial in Patients with Type 2 Diabetes Mellitus in a Managed Care Setting. Endocrine Practice. https://doi.org/10.4158/ep10401.or

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.